SEC Form 4 · accession 0001600620-26-000068
Aurinia Pharmaceuticals Inc. · AUPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen P. Robertson
Officer — Chief Legal Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 11, 2026 · 4:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001600620
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 10, 2026 | S | 11,939 | $15.95 | D | 588,848 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award.
- F2The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.